Top

Hernia

Published in:

17-06-2021 | Losartan | Original Article

Losartan modifies mesh integration after abdominal wall repair: an experimental study

Authors: M. E. Peña, C. A. Angeramo, F. Schlottmann, E. E. Sadava

Published in: Hernia | Issue 3/2022

Abstract

Purpose

Angiotensin II (AT II) receptor blockers have previously shown to reduce inflammatory response in many settings. We aimed to assess the effects of ATII receptor blocker (Losartan) on mesh integration after abdominal wall repair in a rat model.

Methods

A total of 16 Wistar-Kyoto (WKY) and 16 previously hypertensive (SHRSP) rats were isolated. An acute ventral hernia followed by a bridged repair with heavyweight polypropylene mesh was performed. Subjects received either normal saline (WKY-C n = 8 and SHRPS-C n = 8) or 40 mg/kg losartan (WKY-L n = 8) and SHRPS-L n = 8) in the postoperative period. Blood pressure was recorded preoperatively and weekly after surgery. Necropsy with en-bloc resection of the abdominal wall was performed at postoperative day 30. Macroscopic and microscopic evaluations of the specimens were conducted. H&E and Masson’s trichrome were used for histologic evaluation.

Results

Both groups receiving Losartan showed a significant reduction of blood pressure after surgery (WKY-L: 130/85 vs 116/81 mmHg, SHRPS-L: 176/137 vs 122/101 mmHg, p < 0.01). A significant reduction in mesh incorporation and adherence scores were also observed on macroscopic analysis in Losartan groups (p < 0.01 and p = 0.02, respectively). Microscopically, higher immature fibroplasia was observed after Losartan, with a significant reduction in scar plate formation and inflammatory response on the prosthetic surface (p = 0.04 and p = 0.02, respectively).

Conclusion

Losartan modifies the interaction between the host tissue and the prosthesis. An impairment in mesh integration and immature fibroplasia in both normotensive and hypertensive rats detected in our model warrants further research.

Rutkow IM (2003) Demographic and socioeconomic aspects of hernia repair in the United States in 2003. Surg Clin North Am. https://doi.org/10.1016/S0039-6109(03)00132-4CrossRefPubMed

Poulose BK, Shelton J, Phillips S, Moore D, Nealon W, Penson D, Beck W, Holzman MD (2012) Epidemiology and cost of ventral hernia repair: making the case for hernia research. Hernia 16(2):179–183. https://doi.org/10.1007/s10029-011-0879-9CrossRefPubMed

HerniaSurge Group (2018) International guidelines for groin hernia management. Hernia 22(1):1–165. https://doi.org/10.1007/s10029-017-1668-xCrossRef

Henriksen NA, Montgomery A, Kaufmann R, Berrevoet F, East B, Fischer J, Hope W, Klassen D, Lorenz R, Renard Y, Garcia Urena MA, Simons MP (2020) European and Americas Hernia Societies (EHS and AHS). Guidelines for treatment of umbilical and epigastric hernias from the European Hernia Society and Americas Hernia Society. Br J Surg 107(3):171–190. https://doi.org/10.1002/bjs.11489CrossRefPubMed

Luijendijk RW, Hop WC, van den Tol MP, de Lange DC, Braaksma MM, IJzermans JN, Boelhouwer RU, de Vries BC, Salu MK, Wereldsma JC, Bruijninckx CM, Jeekel J (2000) A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med 10;343(6):392–8. https://doi.org/10.1056/NEJM200008103430603

Sadava EE, Peña ME, Schlottmann F (2019) Should we routinely close the fascial defect in laparoscopic ventral and incisional hernia repair? J Laparoendosc Adv Surg Tech A 29(6):856–859. https://doi.org/10.1089/lap.2019.0088CrossRefPubMed

Gonzalez R, Fugate K, McClusky D 3rd, Ritter EM, Lederman A, Dillehay D, Smith CD, Ramshaw BJ (2005) Relationship between tissue ingrowth and mesh contraction. World J Surg 29(8):1038–1043. https://doi.org/10.1007/s00268-005-7786-0CrossRefPubMed

Petro CC, Nahabet EH, Criss CN, Orenstein SB, Von Recum HA, Novitsky YW, Rosen MJ (2015) Central failures of lightweight monofilament polyester mesh causing hernia recurrence: a cautionary note. Hernia 19(1):155–159. https://doi.org/10.1007/s10029-014-1237-5CrossRefPubMed

Parker MJ, Kim RC, Barrio M, Socas J, Reed LR, Nakeeb A, House MG, Ceppa EP (2020) A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients. Surg Endosc. https://doi.org/10.1007/s00464-020-08009-1CrossRefPubMed

10.

Artsen AM, Rytel M, Liang R, King GE, Meyn L, Abramowitch SD, Moalli PA (2019) Mesh induced fibrosis: the protective role of T regulatory cells. Acta Biomater 96:203–210. https://doi.org/10.1016/j.actbio.2019.07.031CrossRefPubMedPubMedCentral

11.

Sadava EE, Krpata DM, Gao Y, Rosen MJ, Novitsky YW (2014) Wound healing process and mediators: Implications for modulations for hernia repair and mesh integration. J Biomed Mater Res A 102(1):295–302. https://doi.org/10.1002/jbm.a.34676CrossRefPubMed

12.

Benigni A, Cassis P, Remuzzi G (2010) Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2(7):247–257. https://doi.org/10.1002/emmm.201000080CrossRefPubMedPubMedCentral

13.

Suzuki Y, Ruiz-Ortega M, Egido J (2000) Angiotensin II: A double-edged sword in inflammation. J Nephrol 13(Suppl 3):S101–S110PubMed

14.

Ruiz-Ortega M, Lorenzo O, Egido J (2000) Angiotensin III increases MCP-1 and activates NF-B and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 57:2285–2298. https://doi.org/10.1046/j.1523-1755.2000.00089.xCrossRefPubMed

15.

Wu L, Chen K, Xiao J, Xin J, Zhang L, Li X, Li L, Si J, Wang L, Ma K (2020) Angiotensin II induces RAW264.7 macrophage polarization to the M1-type through the connexin 43/NF-κB pathway. Mol Med Rep 21(5):2103–2112. https://doi.org/10.3892/mmr.2020.11023CrossRefPubMedPubMedCentral

16.

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J (2016) Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 Countries. Circulation 134(6):441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912CrossRefPubMedPubMedCentral

17.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71(6):e13–e115. https://doi.org/10.1161/HYP.0000000000000065CrossRefPubMed

18.

Oztürk CN, Tezel E, Yalçın O (2011) Evaluation of the effects of losartan on a random pattern skin flap model in rats. Ulus Travma Acil Cerrahi Derg 17(2):97–102CrossRef

19.

Biondo-Simões Mde L, Zazula AD, Gomes AB, Poncio C, Torres LF, Borsato KS (2006) Influence of arterial hypertension treated with losartan on skin healing in rats. Acta Cir Bras 21(3):144–150. https://doi.org/10.1590/s0102-86502006000300005CrossRefPubMed

20.

Criss CN, Gao Y, De Silva G, Yang J, Anderson JM, Novitsky YW, Soltanian H, Rosen MJ (2014) The effects of Losartan on abdominal wall fascial healing. Hernia 19(4):645–650. https://doi.org/10.1007/s10029-014-1241-9CrossRefPubMed

21.

Feng M, Whitesall S, Zhang Y, Beibel M, D’Alecy L, DiPetrillo K (2008) Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21(12):1288–1291. https://doi.org/10.1038/ajh.2008.301CrossRefPubMed

22.

Jansen JA, Dhert WJ, van der Waerden JP, von Recum AF (1994) Semi-quantitative and qualitative histologic analysis method for the evaluation of implant biocompatibility. J Invest Surg 7(2):123–134. https://doi.org/10.3109/08941939409015356CrossRefPubMed

23.

Harrell AG, Novitsky YW, Cristiano JA, Gersin KS, Norton HJ, Kercher KW, Heniford BT (2007) Prospective histologic evaluation of intra-abdominal prosthetics four months after implantation in a rabbit model. Surg Endosc 21(7):1170–1174. https://doi.org/10.1007/s00464-006-9147-yCrossRefPubMed

24.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365(9455):217–223. https://doi.org/10.1016/S0140-6736(05)17741-1CrossRefPubMed

25.

Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K (2008) Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 31(9):1711–1717. https://doi.org/10.1291/hypres.31.1711CrossRefPubMed

26.

Koprdova R, Cebova M, Kristek F (2009) Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. Physiol Res 58(3):327–335. https://doi.org/10.33549/physiolres.931528CrossRefPubMed

27.

Gaudet E, Blanc J, Elghozi JL (1995) Effects of losartan on short-term variability of blood pressure in SHR and WKY rats. Fundam Clin Pharmacol 9(1):30–36. https://doi.org/10.1111/j.1472-8206.1995.tb00262.xCrossRefPubMed

28.

Chan P, Liu JC, Tong YC, Chen YJ, Wang CC, Tomlinson B, Cheng JT (1999) Effects of losartan on the sexual behavior of male rats. Pharmacology 58(3):132–139. https://doi.org/10.1159/000028275CrossRefPubMed

29.

Gay-Jordi G, Guash E, Benito B, Brugada J, Nattel S, Mont L, Serrano-Mollar A (2013) Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. PLoS ONE 8(2):e55427. https://doi.org/10.1371/journal.pone.0055427CrossRefPubMedPubMedCentral

30.

Wang L, Li J, Li D (2015) Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway. Int J Clin Exp Pathol 8(1):466–473PubMedPubMedCentral

31.

Wei YH, Jun L, Qiang CJ (2004) Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci 49(10):1589–1594. https://doi.org/10.1023/b:ddas.0000043369.88701.5bCrossRefPubMed

32.

He P, Li D, Zhang B (2014) Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. Mol Med Rep 10(2):638–644. https://doi.org/10.3892/mmr.2014.2304CrossRefPubMed

33.

Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I, Díez J (1999) Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17(1):107–114. https://doi.org/10.1097/00004872-199917010-00016CrossRefPubMed

34.

Zheng B, Fang QQ, Wang XF, Shi BH, Zhao WY, Chen CY, Zhang MX, Zhang LY, Hu YY, Shi P, Ma L, Tan WQ (2019) The effect of topical ramipril and losartan cream in inhibiting scar formation. Biomed Pharmacother 118:109394. https://doi.org/10.1016/j.biopha.2019.109394CrossRefPubMed

35.

Petro CC, Prabhu AS (2018) Preoperative Planning and Patient Optimization. Surg Clin North Am 98(3):483–497. https://doi.org/10.1016/j.suc.2018.01.005CrossRefPubMed

36.

Krpata DM, Criss CN, Gao Y, Sadava EE, Anderson JM, Novitsky YW, Rosen MJ (2013) Effects of weight reduction surgery on the abdominal wall fascial wound healing process. J Surg Res 184(1):78–83. https://doi.org/10.1016/j.jss.2013.05.034CrossRefPubMed

37.

Majumder A, Gao Y, Sadava EE, Anderson JM, Novitsky YW (2016) Cell-coating affects tissue integration of synthetic and biologic meshes: comparative analysis of the onlay and underlay mesh positioning in rats. Surg Endosc 30(10):4445–4453. https://doi.org/10.1007/s00464-016-4764-6CrossRefPubMed

Title: Losartan modifies mesh integration after abdominal wall repair: an experimental study
Authors: M. E. Peña
C. A. Angeramo
F. Schlottmann
E. E. Sadava
Publication date: 17-06-2021
Publisher: Springer Paris
Keyword: Losartan
Published in: Hernia / Issue 3/2022
Print ISSN: 1265-4906
Electronic ISSN: 1248-9204
DOI: https://doi.org/10.1007/s10029-021-02444-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Losartan modifies mesh integration after abdominal wall repair: an experimental study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2022

Tanaka score predicts surgical intensive care admission following abdominal wall reconstruction

What is the reality in outpatient vs inpatient groin hernia repair? An analysis from the Herniamed Registry

Adaptation and validation of the Carolinas Comfort Scale: a questionnaire-based cross-sectional study

Acceptability and barriers to adopting physical therapy and rehabilitation as standard of care in hernia disease: a prospective national survey of providers and preliminary data

Randomized control trial evaluating the use of a shared decision-making aid for older ventral hernia patients in the Geriatric Assessment and Medical Preoperative Screening (GrAMPS) Program

Geriatric assessment and medical preoperative screening (GrAMPS) program for older hernia patients